Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof

1. A pharmaceutical formulation comprising a mixture of free quinolone antibiotic agent, a quinolone antibiotic agent encapsulated in a plurality of liposomes, and a pharmaceutical excipient, wherein the formulation is a solution or a suspension, the ratio by weight of the free quinolone antibiotic agent to the encapsulated quinolone antibiotic agent is between about 1:10 and about 10:1, and the lipid component of the plurality of liposomes consists of a phospholipid and a sterol.

2. The pharmaceutical formulation of claim 1 , wherein the free quinolone antibiotic agent is a fluoroquinolone and the quinolone antibiotic agent encapsulated in the plurality of liposomes is a fluoroquinolone.

3. The pharmaceutical formulation of claim 1 , wherein the free quinolone antibiotic agent and the quinolone antibiotic agent encapsulated in the plurality of liposomes is independently, ciprofloxacin, enoxacin, gatifloxacin, grepafloxacin, levofloxacin, lomefloxacin, moxifloxacin, nalidixic acid, norfloxacin, ofloxacin, sparfloxacin, trovafloxacin, oxolinic acid, gemifloxacin, or perfloxacin.

4. The pharmaceutical formulation of claim 1 , wherein the free quinolone antibiotic agent is ciprofloxacin and the quinolone antibiotic agent encapsulated in the plurality of liposomes is ciprofloxacin.

5. The pharmaceutical formulation of claim 1 , wherein the phospholipid is a phosphatidylcholine.

6. The pharmaceutical formulation of claim 5 , wherein the phosphatidylcholine is hydrogenated soy phosphatidylcholine (HSPC).

7. The pharmaceutical formulation of claim 5 , wherein the sterol is cholesterol.

8. The pharmaceutical formulation of claim 6 , wherein the sterol is cholesterol.

9. The pharmaceutical formulation of claim 1 , wherein the phospholipid is hydrogenated soy phosphatidylcholine (HSPC), the sterol is cholesterol, the free quinolone antibiotic agent is a fluoroquinolone and the quinolone antibiotic agent encapsulated in the plurality of liposomes is a fluoroquinolone.

10. The pharmaceutical formulation of claim 1 , wherein the phospholipid is a phosphatidylcholine, the free quinolone antibiotic agent is ciprofloxacin and the quinolone antibiotic agent encapsulated in the plurality of liposomes is ciprofloxacin.

11. The pharmaceutical formulation of claim 1 , wherein the phospholipid is a phosphatidylcholine, the sterol is a cholesterol, the free quinolone antibiotic agent is ciprofloxacin and the quinolone antibiotic agent encapsulated in the plurality of liposomes is ciprofloxacin.

12. The pharmaceutical formulation of claim 1 , wherein the phospholipid is a hydrogenated soy phosphatidylcholine (HSPC), the sterol is cholesterol, the free quinolone antibiotic agent is ciprofloxacin and the quinolone antibiotic agent encapsulated in the plurality of liposomes is ciprofloxacin.

13. The pharmaceutical formulation of claim 12 , wherein the formulation is an aerosol.

14. The pharmaceutical formulation of claim 1 , wherein the ratio by weight of free quinolone antibiotic agent to the encapsulated quinolone antibiotic agent is between about 1:2 and about 2:1.

15. The pharmaceutical formulation of claim 12 , wherein the ratio by weight of free ciprofloxacin to the encapsulated ciprofloxacin is between about 1:2 and about 2:1.

16. The pharmaceutical formulation of claim 15 , wherein the formulation is an aerosol.

17. A system for treating or providing prophylaxis against a pulmonary infection comprising:

a) the pharmaceutical formulation of claim 1 , and

b) an inhalation delivery device.

18. The system of claim 17 , wherein the inhalation delivery device is a nebulizer, the phospholipid is hydrogenated soy phosphatidylcholine (HSPC), the sterol is cholesterol, the free quinolone antibiotic agent is ciprofloxacin and the quinolone antibiotic agent encapsulated in the plurality of liposomes is ciprofloxacin.

19. The system of claim 18 , wherein the nebulizer is a single dose nebulizer.

20. A method for treating a pulmonary infection in a patient in need thereof comprising, nebulizing the pharmaceutical formulation of claim 1 , to generate a nebulized pharmaceutical formulation, administering the nebulized pharmaceutical formulation to the lungs of the patient.

21. A method for treating a pulmonary infection in a patient in need thereof comprising, nebulizing the pharmaceutical formulation of claim 11 , to generate a nebulized pharmaceutical formulation, administering the nebulized pharmaceutical formulation to the lungs of the patient.

22. A method for treating a pulmonary infection in a patient in need thereof comprising, nebulizing the pharmaceutical formulation of claim 12 , to generate a nebulized pharmaceutical formulation, administering the nebulized pharmaceutical formulation to the lungs of the patient.

23. A method for treating a pulmonary infection in a patient in need thereof comprising, nebulizing the pharmaceutical formulation of claim 15 , to generate a nebulized pharmaceutical formulation, administering the nebulized pharmaceutical formulation to the lungs of the patient.

24. The method of claim 20 , wherein the patient is a bronchiectasis patient.

25. The method of claim 21 , wherein the patient is a bronchiectasis patient.

26. The method of claim 22 , wherein the patient is a bronchiectasis patient.

27. The method of claim 23 , wherein the patient is a bronchiectasis patient.

28. The method of claim 22 , wherein the pulmonary infection is a Pseudomonas Aeruginosa infection.

29. The method of claim 23 , wherein the pulmonary infection is a Pseudomonas Aeruginosa infection.

30. The method of claim 26 , wherein the pulmonary infection is a Pseudomonas Aeruginosa infection.